

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2017**

Commission File Number: **333-219066**

**Clementia Pharmaceuticals Inc.**  
(Translation of registrant's name into English)

**4150 St Catherine Street West, Suite 550**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

---

On September 6, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated September 6, 2017

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Clementia Pharmaceuticals Inc.**  
(Registrant)

Date: September 6, 2017

/s/ MICHAEL SINGER  
Michael Singer  
Chief Financial Officer

**Clementia Pharmaceuticals to Participate in Upcoming Investor Conferences**

MONTREAL, Sept. 06, 2017 (GLOBE NEWSWIRE) – Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical stage biopharmaceutical company, today announced that Dr. Clarissa Desjardins, CEO of Clementia Pharmaceuticals, will participate in two upcoming investor conferences:

- Morgan Stanley 15<sup>th</sup> Annual Global Healthcare Conference at the Grand Hyatt New York, on Monday, September 11, 2017 at 4:50 pm ET
- LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology at the Lotte New York Palace hotel, on Wednesday, September 27, 2017, at 2:00 pm ET

The presentations at the Morgan Stanley and Leerink conferences will be webcast live and available for replay at [investor.clementiapharma.com](http://investor.clementiapharma.com).

**About Clementia Pharmaceuticals Inc.**

Clementia is a clinical stage biopharmaceutical company committed to delivering treatments to people who have none. The company is developing its lead candidate palovarotene, a novel RAR $\gamma$  agonist, to treat Fibrodysplasia Ossificans Progressiva (FOP), Multiple Osteochondromas (MO), and other diseases. For more information, please visit [www.clementiapharma.com](http://www.clementiapharma.com).

**Cautionary Note Regarding Forward-Looking Statements**

*This press release may include "forward-looking statements" within the meaning of the applicable securities laws. Each forward-looking statement contained in this press release is subject to known and unknown risks and uncertainties and other unknown factors that could cause actual results to differ materially from historical results and those expressed or implied by such statement. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Applicable risks and uncertainties include, among others, our ability to generate revenue and become profitable; the risks related to our heavy reliance on palovarotene, our only current product candidate; the risks associated with the development of palovarotene and any future product candidate, including the demonstration of efficacy and safety; our heavy dependence on licensed intellectual property, including our ability to source and maintain licenses from third-party owners; as well as the risks identified under the heading "Risk Factors" in our Prospectus on Form 424(b) filed with the Securities and Exchange Commission ("SEC"), as well as the other information we file with the SEC or on SEDAR. We caution investors not to rely on the forward-looking statements contained in this press release when making an investment decision in our securities. You are encouraged to read our filings with the SEC or on SEDAR, available at [www.sec.gov](http://www.sec.gov) or [www.sedar.com](http://www.sedar.com), for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law.*

Investor/Media Contact:

Joseph Walewicz  
+1-514-940-1080  
[investors@clementiapharma.com](mailto:investors@clementiapharma.com)